Anika Therapeutics

The past year was a profitable year Anika Therapeutics investors

Over the period from December 2015 till December 2016 the stock gained around 28 percent. Anika Therapeutics' stock rose the past 5 years at around 433 percent. Anika Therapeutics's revenues between 2011 and 2015 were very volatile through the time and moved between 71,36 million dollars and 93 million dollars. Anika Therapeutics's net incomes between 2011 and 2015 were very volatile through the time and moved between 8,47 million dollars and 30,76 million dollars.

Anika Therapeutics has it' headquarter based in Bedford. Anika Therapeutics is mostly active in the health care eq. & services sector. Dr. Charles H. Sherwood Ph.D leads the company as CEO. The CFO of the company is Ms. Sylvia Cheung. The global health care companies gained around 102 percent over the period 2006-2016. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-December 2016) there is a plus of 102 percent.

The American company didn't pay out any dividends (in the past 5 years).

Anika Therapeutics financed with relatively a lot of debt

At the end of 2015 the American company's balance sheet was worth 235,75 million dollars. Last year the total debt of the company was 24,9 million dollars. This equals around 10,56 percent of the total balance sheet. The American company's price/earnings-ratio was 20. So the market valued the stock at 20 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the health care company equaled around 564,95 million dollars. At the end of 2015 the American company had around 14,93 million stocks listed.

All Anika Therapeutics's financial reports are available here. More information about Anika Therapeutics can be found it's website. .